Anıl Doğukan Tutal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anıl Doğukan Tutal has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ceren Sağlam Purut
Department of Perinatology, İzmir Atatürk Training and Research Hospital, 35360 İzmir, Türkiye
5 shared publications - Göktürk Han Doğan
Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, Gaziler Cad. No: 468, Yenişehir, Konak, 35020 Izmir, Türkiye
4 shared publications - Serhat Sarıkaya
Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, Gaziler Cad. No: 468, Yenişehir, Konak, 35020 Izmir, Türkiye
4 shared publications - Göksever Akpınar
Department of General Surgery, İzmir Tepecik Training and Research Hospital, University of Health Sciences, 35020 Izmir, Türkiye
2 shared publications - Mehmet Gokcu
Department of Gynecologic Oncology, Tepecik Education and Research Hospital, Izmir, Turkey
2 shared publications - Sercan Kantarcı
University of Health Sciences Tepecik Training and Research Hospital, Department of Obstetrics and Gynecology, İzmir, Türkiye
2 shared publications
Latest Publications
- Open Access
Serum CA19-9 Adds Histotype Information to CA125 in Epithelial Ovarian Cancer: A Retrospective Cohort Study of 157 Chemotherapy-Naive Patients
Background and Objectives: Histological subtype in epithelial ovarian cancer determines chemosensitivity and prognosis but is usually confirmed only on the surgical specimen. We asked whether any preoperative serum tumour marker, or any ratio between two, is associated with non-serous histology and adds to International Federation of Gynecology and Obstetrics (FIGO) stage. Materials and Methods: Retrospective cohort of 157 women operated on for epithelial ovarian cancer in 2016–2024 with complete chemotherapy-naive CA125, carcinoembryonic antigen (CEA), CA19-9 and CA15-3 values (pre-cycle-one values in 64 neoadjuvant patients). Four markers and six pairwise ratios were assessed by Mann–Whitney tests with Benjamini–Hochberg correction, receiver-operating-characteristic analysis and Firth penalised regression; discrimination was internally validated by bootstrap resampling that repeated the selection of the leading index. Results: Twenty-four tumours (15.3%) were non-serous. The CA125/CA19-9 ratio ranked first (area under the curve 0.796, 95% confidence interval 0.696–0.883) but was not superior to CA125 alone (0.708; p = 0.072), and stage alone performed comparably (0.805). Adding the ratio to stage improved fit (p = 0.001; odds ratio 0.36 per ten-fold increase, 0.17–0.71; selection-adjusted permutation p = 0.021). Optimism-corrected areas were 0.766 for the ratio alone and 0.869 for stage plus ratio; CA15-3/CA19-9 and CA19-9 alone added to stage similarly. The threshold of 12.2 was unstable (bootstrap range 2.6–58.7) and discrimination was 0.575 in early-stage disease. Raised CA19-9 arose from clear cell (p = 0.002) and mucinous (p = 0.022) but not endometrioid tumours (p = 0.92). Conclusions: CA19-9 carries histotype information beyond CA125 and stage, arising from clear cell and mucinous tumours, whether expressed alone or as a ratio; neither is usable as a stand-alone preoperative test or to guide treatment. The finding is hypothesis-generating and requires external validation alongside human epididymis protein 4 (HE4) and the Risk of Ovarian Malignancy Algorithm (ROMA).
Open AccessSerum CA19-9 Adds Histotype Information to CA125 in Epithelial Ovarian Cancer: A Retrospective Cohort Study of 157 Chemotherapy-Naive Patients
Background and Objectives: Histological subtype in epithelial ovarian cancer determines chemosensitivity and prognosis but is usually confirmed only on the surgical specimen. We asked whether any preoperative serum tumour marker, or any ratio between two, is associated with non-serous histology and adds to International Federation of Gynecology and Obstetrics (FIGO) stage. Materials and Methods: Retrospective cohort of 157 women operated on for epithelial ovarian cancer in 2016–2024 with complete chemotherapy-naive CA125, carcinoembryonic antigen (CEA), CA19-9 and CA15-3 values (pre-cycle-one values in 64 neoadjuvant patients). Four markers and six pairwise ratios were assessed by Mann–Whitney tests with Benjamini–Hochberg correction, receiver-operating-characteristic analysis and Firth penalised regression; discrimination was internally validated by bootstrap resampling that repeated the selection of the leading index. Results: Twenty-four tumours (15.3%) were non-serous. The CA125/CA19-9 ratio ranked first (area under the curve 0.796, 95% confidence interval 0.696–0.883) but was not superior to CA125 alone (0.708; p = 0.072), and stage alone performed comparably (0.805). Adding the ratio to stage improved fit (p = 0.001; odds ratio 0.36 per ten-fold increase, 0.17–0.71; selection-adjusted permutation p = 0.021). Optimism-corrected areas were 0.766 for the ratio alone and 0.869 for stage plus ratio; CA15-3/CA19-9 and CA19-9 alone added to stage similarly. The threshold of 12.2 was unstable (bootstrap range 2.6–58.7) and discrimination was 0.575 in early-stage disease. Raised CA19-9 arose from clear cell (p = 0.002) and mucinous (p = 0.022) but not endometrioid tumours (p = 0.92). Conclusions: CA19-9 carries histotype information beyond CA125 and stage, arising from clear cell and mucinous tumours, whether expressed alone or as a ratio; neither is usable as a stand-alone preoperative test or to guide treatment. The finding is hypothesis-generating and requires external validation alongside human epididymis protein 4 (HE4) and the Risk of Ovarian Malignancy Algorithm (ROMA).
- Open Access
- 5 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (19) , 3221
Can Routine Preoperative Endoscopy and Colonoscopy Be Meaningful for the Surgery and Postoperative Course of Patients with Advanced Ovarian Cancer? A Single-Centre Retrospective Cohort Study
Background/Objectives: Bowel resection is often required for complete cytoreduction in advanced ovarian cancer, and some units perform upper gastrointestinal endoscopy and colonoscopy beforehand. We compared the endoscopic biopsy findings with the histopathology of the resected bowel and examined determinants of survival. Methods: Eighty-three consecutive women with FIGO stage III–IV serous ovarian cancer cytoreduced to no macroscopic residual disease between 2015 and 2021 were reviewed retrospectively; all had undergone both examinations and completed adjuvant carboplatin–paclitaxel. Results: Bowel resection was performed in 20 women (24.1%). Serosal involvement was reported in 15 specimens and no tumour in four; mucosal invasion was reported in none (95% CI 0–16.8%). Eighteen patients (21.7%) were biopsied endoscopically; no biopsy was malignant. Over a median follow-up of 72 months, 50 women (60.2%) developed recurrence (28 confirmed histologically and 22 diagnosed from imaging and CA-125; recurrence was ascertained retrospectively, which limits the interpretation of disease-free survival) and 44 (53.0%) died. Recurrence was no more frequent in biopsied than in non-biopsied patients (8/18 vs. 42/65, p = 0.174) or after resection (10/20 vs. 40/63, p = 0.306). Age showed an exploratory association with disease-free (HR 1.03/year, 95% CI 1.00–1.06) and overall survival (HR 1.04, 1.00–1.07). Conclusions: In this cohort, no preoperative endoscopic biopsy was malignant and no resected specimen was reported to show mucosal invasion, supporting a limited role for routine endoscopy in assessing bowel wall involvement; its diagnostic accuracy and its value for excluding a gastrointestinal primary could not be assessed.
- 5 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (19) , 3221
Open AccessCan Routine Preoperative Endoscopy and Colonoscopy Be Meaningful for the Surgery and Postoperative Course of Patients with Advanced Ovarian Cancer? A Single-Centre Retrospective Cohort Study
Background/Objectives: Bowel resection is often required for complete cytoreduction in advanced ovarian cancer, and some units perform upper gastrointestinal endoscopy and colonoscopy beforehand. We compared the endoscopic biopsy findings with the histopathology of the resected bowel and examined determinants of survival. Methods: Eighty-three consecutive women with FIGO stage III–IV serous ovarian cancer cytoreduced to no macroscopic residual disease between 2015 and 2021 were reviewed retrospectively; all had undergone both examinations and completed adjuvant carboplatin–paclitaxel. Results: Bowel resection was performed in 20 women (24.1%). Serosal involvement was reported in 15 specimens and no tumour in four; mucosal invasion was reported in none (95% CI 0–16.8%). Eighteen patients (21.7%) were biopsied endoscopically; no biopsy was malignant. Over a median follow-up of 72 months, 50 women (60.2%) developed recurrence (28 confirmed histologically and 22 diagnosed from imaging and CA-125; recurrence was ascertained retrospectively, which limits the interpretation of disease-free survival) and 44 (53.0%) died. Recurrence was no more frequent in biopsied than in non-biopsied patients (8/18 vs. 42/65, p = 0.174) or after resection (10/20 vs. 40/63, p = 0.306). Age showed an exploratory association with disease-free (HR 1.03/year, 95% CI 1.00–1.06) and overall survival (HR 1.04, 1.00–1.07). Conclusions: In this cohort, no preoperative endoscopic biopsy was malignant and no resected specimen was reported to show mucosal invasion, supporting a limited role for routine endoscopy in assessing bowel wall involvement; its diagnostic accuracy and its value for excluding a gastrointestinal primary could not be assessed.
- Open Access
- 18 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7250
vNOTES Versus Laparoscopic Lateral Suspension for Advanced Pelvic Organ Prolapse: A Single-Center, Single-Surgeon Retrospective Cohort Study
Background/Objectives: Vaginal natural orifice transluminal endoscopic surgery lateral suspension (vNOTES-LS) may reduce the perioperative burden of conventional laparoscopic lateral suspension (LLS), but comparative evidence remains limited. We compared perioperative, anatomical, safety, and patient-reported outcomes. Methods: This single-center retrospective cohort included 97 women with stage III–IV pelvic organ prolapse who underwent vNOTES-LS (n = 33) or LLS (n = 64) and completed 12-month follow-up. The primary outcome was anatomical success at 12 months. Results: Operating time was shorter with vNOTES-LS (78.0 ± 16.6 vs. 110.0 ± 14.2 min; p < 0.001), as were estimated blood loss, hospitalization, and 24-h pain scores. After adjustment, vNOTES-LS was associated with a 31.7-min shorter operating time (95% CI, −38.7 to −24.6; p < 0.001). Anatomical success was 87.9% versus 89.1% (p = 1.000; RR, 0.99; 95% CI, 0.85–1.15), with an absolute risk difference of −1.2 percentage points (95% CI, −14.7 to 12.3). Cumulative mesh exposure within 12 months was 9.1% and 9.4%, respectively. No statistically significant between-group differences were detected in recurrence, measured safety outcomes, or longitudinal changes in the Pelvic Floor Distress Inventory-20 (PFDI-20), Pelvic Floor Impact Questionnaire-7 (PFIQ-7), and 12-item Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Conclusions: vNOTES-LS was associated with shorter operating time and favorable early perioperative outcomes. Observed 12-month anatomical success rates were not statistically significantly different; however, equivalence or non-inferiority cannot be concluded.
- 18 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7250
Open AccessvNOTES Versus Laparoscopic Lateral Suspension for Advanced Pelvic Organ Prolapse: A Single-Center, Single-Surgeon Retrospective Cohort Study
Background/Objectives: Vaginal natural orifice transluminal endoscopic surgery lateral suspension (vNOTES-LS) may reduce the perioperative burden of conventional laparoscopic lateral suspension (LLS), but comparative evidence remains limited. We compared perioperative, anatomical, safety, and patient-reported outcomes. Methods: This single-center retrospective cohort included 97 women with stage III–IV pelvic organ prolapse who underwent vNOTES-LS (n = 33) or LLS (n = 64) and completed 12-month follow-up. The primary outcome was anatomical success at 12 months. Results: Operating time was shorter with vNOTES-LS (78.0 ± 16.6 vs. 110.0 ± 14.2 min; p < 0.001), as were estimated blood loss, hospitalization, and 24-h pain scores. After adjustment, vNOTES-LS was associated with a 31.7-min shorter operating time (95% CI, −38.7 to −24.6; p < 0.001). Anatomical success was 87.9% versus 89.1% (p = 1.000; RR, 0.99; 95% CI, 0.85–1.15), with an absolute risk difference of −1.2 percentage points (95% CI, −14.7 to 12.3). Cumulative mesh exposure within 12 months was 9.1% and 9.4%, respectively. No statistically significant between-group differences were detected in recurrence, measured safety outcomes, or longitudinal changes in the Pelvic Floor Distress Inventory-20 (PFDI-20), Pelvic Floor Impact Questionnaire-7 (PFIQ-7), and 12-item Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Conclusions: vNOTES-LS was associated with shorter operating time and favorable early perioperative outcomes. Observed 12-month anatomical success rates were not statistically significantly different; however, equivalence or non-inferiority cannot be concluded.
- 1 September 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (9) , 988-992
Adnexal masses during pregnancy
Aim Routine ultrasound scanning for fetal anomaly detection has enabled increased recognition of adnexal masses during pregnancy in recent years. In addition to incidental detection during routine antenatal follow-up, adnexal masses may also be identified in pregnant women presenting with an acute abdomen. In this study, we aimed to evaluate the clinicopathological features of lesions detected in pregnant women presenting with acute abdomen and in those with incidentally detected adnexal masses during routine antenatal clinical and radiological examinations. Methods Pregnant women evaluated between 2013 and 2020 who presented with acute abdomen or had incidentally detected adnexal masses during routine clinical and radiological examinations were retrospectively identified from the clinical databases of the Departments of General Surgery and Obstetrics and Gynecology. Patients with ectopic pregnancy were excluded. Results We included 44 pregnant women with a median age of 28.5 years (range, 18–42 years). Ten patients presented during the first trimester, 24 during the second trimester, and 10 during the third trimester. Most patients did not require surgery. Among surgically treated patients, benign lesions predominated, with mature cystic teratoma being the most common benign neoplasm. Conclusion The types of adnexal lesions detected during pregnancy (non-neoplastic and neoplastic; benign, borderline, or malignant), their frequencies, and the gestational trimester at diagnosis were consistent with the published literature. Functional ovarian cysts were the leading cause of adnexal masses during the first trimester, whereas neoplastic lesions were more frequently encountered during the second and third trimesters. Mature cystic teratoma was the most common benign neoplasm. Borderline and malignant lesions were uncommon. Treatment-related conditions and uterine anatomical anomalies should also be considered in the differential diagnosis because they may mimic adnexal masses during pregnancy.
- 1 September 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (9) , 988-992
Adnexal masses during pregnancy
Aim Routine ultrasound scanning for fetal anomaly detection has enabled increased recognition of adnexal masses during pregnancy in recent years. In addition to incidental detection during routine antenatal follow-up, adnexal masses may also be identified in pregnant women presenting with an acute abdomen. In this study, we aimed to evaluate the clinicopathological features of lesions detected in pregnant women presenting with acute abdomen and in those with incidentally detected adnexal masses during routine antenatal clinical and radiological examinations. Methods Pregnant women evaluated between 2013 and 2020 who presented with acute abdomen or had incidentally detected adnexal masses during routine clinical and radiological examinations were retrospectively identified from the clinical databases of the Departments of General Surgery and Obstetrics and Gynecology. Patients with ectopic pregnancy were excluded. Results We included 44 pregnant women with a median age of 28.5 years (range, 18–42 years). Ten patients presented during the first trimester, 24 during the second trimester, and 10 during the third trimester. Most patients did not require surgery. Among surgically treated patients, benign lesions predominated, with mature cystic teratoma being the most common benign neoplasm. Conclusion The types of adnexal lesions detected during pregnancy (non-neoplastic and neoplastic; benign, borderline, or malignant), their frequencies, and the gestational trimester at diagnosis were consistent with the published literature. Functional ovarian cysts were the leading cause of adnexal masses during the first trimester, whereas neoplastic lesions were more frequently encountered during the second and third trimesters. Mature cystic teratoma was the most common benign neoplasm. Borderline and malignant lesions were uncommon. Treatment-related conditions and uterine anatomical anomalies should also be considered in the differential diagnosis because they may mimic adnexal masses during pregnancy.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (11)
Same margin, different lesion: margin subtype, glandular involvement, and endocervical curettage status as predictors of residual CIN2+ at repeat loop electrosurgical excision procedure: An 11-year retrospective cohort study
SUMMARY OBJECTIVE: The aim of this study was to assess how initial loop electrosurgical excision procedure margin subtype, glandular involvement, endocervical curettage findings, and specimen size relate to re-loop electrosurgical excision procedure pathology and receipt of further surgery. METHODS: In this retrospective cohort study, 287 patients undergoing re-loop electrosurgical excision procedure at a tertiary center (2015–2025) were reviewed. Initial margin status was classified as margin continuity, margin adjacency, or non-evaluable margin. Associations with re-loop electrosurgical excision procedure pathology, residual CIN2+ disease, and receipt of a third surgical intervention were assessed using chi-square/Fisher-Freeman-Halton tests, Cohen's kappa, and multivariate logistic regression. RESULTS: Initial and re-loop electrosurgical excision procedure pathology showed a significant group-level association (p=0.039) but no case-by-case agreement beyond chance (kappa=-0.009, p=0.754); most patients with initial CIN2/3 had CIN1 at re-loop electrosurgical excision procedure. Margin adjacency independently predicted residual CIN2+ disease at repeat loop electrosurgical excision procedure (OR 11.045, p=0.049), as did glandular involvement (OR 1.938, p=0.035). Among patients with negative re-loop electrosurgical excision procedure margins, residual CIN2+ disease was identified within the specimen in 27.1%, and human papillomavirus test negativity at the first follow-up visit was 88.2%, varying by genotype. Positive margin (OR 333.33, p<0.001) and positive endocervical curettage (OR 41.67, p<0.001) at repeat loop electrosurgical excision procedure were the strongest predictors of receiving a third surgical intervention. CONCLUSION: Margin adjacency and glandular involvement independently predicted residual CIN2+ at repeat loop electrosurgical excision procedure, whereas positive margins and positive endocervical curettage at re-loop electrosurgical excision procedure were strongly associated with receipt of a third surgical intervention. Post-loop electrosurgical excision procedure follow-up should integrate margin subtype, glandular involvement, endocervical curettage findings, and human papillomavirus surveillance rather than rely on margin status alone; genotype-specific differences in human papillomavirus test negativity require confirmation in larger cohorts.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (11)
Open AccessSame margin, different lesion: margin subtype, glandular involvement, and endocervical curettage status as predictors of residual CIN2+ at repeat loop electrosurgical excision procedure: An 11-year retrospective cohort study
SUMMARY OBJECTIVE: The aim of this study was to assess how initial loop electrosurgical excision procedure margin subtype, glandular involvement, endocervical curettage findings, and specimen size relate to re-loop electrosurgical excision procedure pathology and receipt of further surgery. METHODS: In this retrospective cohort study, 287 patients undergoing re-loop electrosurgical excision procedure at a tertiary center (2015–2025) were reviewed. Initial margin status was classified as margin continuity, margin adjacency, or non-evaluable margin. Associations with re-loop electrosurgical excision procedure pathology, residual CIN2+ disease, and receipt of a third surgical intervention were assessed using chi-square/Fisher-Freeman-Halton tests, Cohen's kappa, and multivariate logistic regression. RESULTS: Initial and re-loop electrosurgical excision procedure pathology showed a significant group-level association (p=0.039) but no case-by-case agreement beyond chance (kappa=-0.009, p=0.754); most patients with initial CIN2/3 had CIN1 at re-loop electrosurgical excision procedure. Margin adjacency independently predicted residual CIN2+ disease at repeat loop electrosurgical excision procedure (OR 11.045, p=0.049), as did glandular involvement (OR 1.938, p=0.035). Among patients with negative re-loop electrosurgical excision procedure margins, residual CIN2+ disease was identified within the specimen in 27.1%, and human papillomavirus test negativity at the first follow-up visit was 88.2%, varying by genotype. Positive margin (OR 333.33, p<0.001) and positive endocervical curettage (OR 41.67, p<0.001) at repeat loop electrosurgical excision procedure were the strongest predictors of receiving a third surgical intervention. CONCLUSION: Margin adjacency and glandular involvement independently predicted residual CIN2+ at repeat loop electrosurgical excision procedure, whereas positive margins and positive endocervical curettage at re-loop electrosurgical excision procedure were strongly associated with receipt of a third surgical intervention. Post-loop electrosurgical excision procedure follow-up should integrate margin subtype, glandular involvement, endocervical curettage findings, and human papillomavirus surveillance rather than rely on margin status alone; genotype-specific differences in human papillomavirus test negativity require confirmation in larger cohorts.
- Open Access
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1244-1251
Evaluation of single-layer versus double-layer suturing of low transverse uterine incisions in cesarean section and follow-up of scars by ultrasound: a prospective randomized controlled study
Background/aim: Cesarean section(CS) is a widely performed operation worldwide. Data about uterine closure is lacking. We aimed to evaluate scar niches and compare the single and double-layer uterine closure after six months following CS.Materials-Methods: A prospective, randomized trial assessed 56 women undergoing single or double-layer uterine closure. None of the patients had previous uterine surgery. The CSs were elective cases. Transvaginal ultrasound was performed six months after CS to assess uterine scar by measuring the width, depth, and length of scar niche and residual myometrial thickness. An experienced sonographer was blinded to the uterine closure technique and the ultrasounds were conducted as unaware of the technique in the postoperative follow-ups. Results: Twenty-eight cases were allocated to each single-layer closure (Group 1) and double-layer closure arm (Group 2). Demographic and clinical characteristics of patients, the width, depth, diameter of the niche, and residual myometrial thickness were similar among groups. There was no difference in uterine scar volume under incision between the two groups. The duration of surgery was about five minutes longer (p=0.048), and hemoglobin loss was about 0.5 g/dl less (p=0.039) in the double-layer group compared to the single-layer. Postmenstrual spotting rates were also similar among groups. Group 1 had two, and Group 2 had one spontaneous pregnancy within six months after CS.Conclusion: The single and double-layer closure techniques do not produce any different impacts on cesarean scar niche features after six months of delivery. In addition, ultrasound might be an important non-invasive diagnostic tool to understand CS scar remodeling.
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1244-1251
Open AccessEvaluation of single-layer versus double-layer suturing of low transverse uterine incisions in cesarean section and follow-up of scars by ultrasound: a prospective randomized controlled study
Background/aim: Cesarean section(CS) is a widely performed operation worldwide. Data about uterine closure is lacking. We aimed to evaluate scar niches and compare the single and double-layer uterine closure after six months following CS.Materials-Methods: A prospective, randomized trial assessed 56 women undergoing single or double-layer uterine closure. None of the patients had previous uterine surgery. The CSs were elective cases. Transvaginal ultrasound was performed six months after CS to assess uterine scar by measuring the width, depth, and length of scar niche and residual myometrial thickness. An experienced sonographer was blinded to the uterine closure technique and the ultrasounds were conducted as unaware of the technique in the postoperative follow-ups. Results: Twenty-eight cases were allocated to each single-layer closure (Group 1) and double-layer closure arm (Group 2). Demographic and clinical characteristics of patients, the width, depth, diameter of the niche, and residual myometrial thickness were similar among groups. There was no difference in uterine scar volume under incision between the two groups. The duration of surgery was about five minutes longer (p=0.048), and hemoglobin loss was about 0.5 g/dl less (p=0.039) in the double-layer group compared to the single-layer. Postmenstrual spotting rates were also similar among groups. Group 1 had two, and Group 2 had one spontaneous pregnancy within six months after CS.Conclusion: The single and double-layer closure techniques do not produce any different impacts on cesarean scar niche features after six months of delivery. In addition, ultrasound might be an important non-invasive diagnostic tool to understand CS scar remodeling.
- Open Access
- 3 November 2016
- Published by Taylor & Francis in Hematology
- Vol. 22 (4) , 248-251
The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation
Background: Iron chelation therapy is one of the mainstays of the management of the patients with β-thalassemia (BT) major. Deferasirox is an oral active iron chelating agent. Proteinuria is one of the potential renal adverse effects of deferasirox, and monthly follow-up for proteinuria is suggested by Food and Drug Administration and European Medicine Agency. Methods: We aimed to investigate the necessity for monthly monitoring for proteinuria among patients with BT on deferasirox. A retrospective laboratory and clinic data review was performed for patients with BT major or intermedia who were treated with deferasirox chelation therapy. All patients were monitored for proteinuria for every 3 or 4 weeks after the initiation of deferasirox with serum creatinine and spot urine protein/creatinine ratios. Results: The median follow-up time of the 37 (36 BT major and one BT intermedia) patients was 44 months. Seven patients (18.9%) developed significant proteinuria (ratio ≥0.8). Of the 1490 measurements, 12 tests (0.8%) were proteinuric. Urine proteinuria resolved in all of the patients during the follow-up. The risk of proteinuria was higher at ages below a cut-off point of 23 years (p = 0.019). Patients, who were on deferasirox at doses above a cut-off dose of 29 mg/kg/day, were found to have higher risk of proteinuria development (p = 0.004). Conclusion: Proteinuria resolves without any complication or major intervention according to our results. Potentially more risky groups (age below 23 years old and receivers above a dose of 29 mg/kg/day) might be suggested to be followed monthly, besides monitoring all of the patients.
- 3 November 2016
- Published by Taylor & Francis in Hematology
- Vol. 22 (4) , 248-251
Open AccessThe questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation
Background: Iron chelation therapy is one of the mainstays of the management of the patients with β-thalassemia (BT) major. Deferasirox is an oral active iron chelating agent. Proteinuria is one of the potential renal adverse effects of deferasirox, and monthly follow-up for proteinuria is suggested by Food and Drug Administration and European Medicine Agency. Methods: We aimed to investigate the necessity for monthly monitoring for proteinuria among patients with BT on deferasirox. A retrospective laboratory and clinic data review was performed for patients with BT major or intermedia who were treated with deferasirox chelation therapy. All patients were monitored for proteinuria for every 3 or 4 weeks after the initiation of deferasirox with serum creatinine and spot urine protein/creatinine ratios. Results: The median follow-up time of the 37 (36 BT major and one BT intermedia) patients was 44 months. Seven patients (18.9%) developed significant proteinuria (ratio ≥0.8). Of the 1490 measurements, 12 tests (0.8%) were proteinuric. Urine proteinuria resolved in all of the patients during the follow-up. The risk of proteinuria was higher at ages below a cut-off point of 23 years (p = 0.019). Patients, who were on deferasirox at doses above a cut-off dose of 29 mg/kg/day, were found to have higher risk of proteinuria development (p = 0.004). Conclusion: Proteinuria resolves without any complication or major intervention according to our results. Potentially more risky groups (age below 23 years old and receivers above a dose of 29 mg/kg/day) might be suggested to be followed monthly, besides monitoring all of the patients.